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Abstract
In 2002, botulinum toxin type A (BoNT/A) was approved by the US Food and 
Drug Administration (FDA) for cosmetic use. However, there may be procedural 
differences between the ways in which a clinician handles, applies and stores 
the product compared to the suggested guidelines of the manufacturer for 
handling and storage. To this end vials (N = 12) of BoNT/A were tested for the 
incidence of microbial contamination followed by challenging the product with a 
selection of microorganisms by culture methods and by using a calcein release 
assay to contaminate multi-dose vials at the single concentration used for 
facial aesthetics. A culture, droplet method was used to count microorganisms 
challenged with the therapeutic product and to compare viability levels in 
appropriate controls as well as measuring their lytic properties via an existing 
cell-free system involving calcein release. Counts of test organisms within the 
droplets, with the product and the controls without the product were undertaken 
using Image J software. The result from the incidence of in-vial contamination 
was inconclusive. Bacterial levels between controls and product challenged 
groups demonstrated no differences in the growth of viable microorganisms 
following immediate contact (p ≥0.05). The cell-free calcein release assay 
demonstrated differences at all time points for low levels of lysis in each case 
with bacterial lipid extract and were statistically significant (p = 0.011). Although 
these data appear to correlate with the minimum inhibitory concentration, the 
additives and vial integrity are also likely to contribute to the maintenance of 
BoNT/A sterility. 
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Introduction
Botulinum toxins are a group of neurotoxins derived from Gram 
positive, anaerobic, spore forming, rod shaped bacteria known as 
Clostridium botulinum, Clostridium butyricum and Clostridium 
baratii. Seven serologically distinct subtypes of the toxin from C. 
botulinum strains are reported [1]. They are designated the code A, B, 
C1,  D, E, F and G and there is a high degree of amino acid sequence 
homology among the various serotypes [2]. Of these, serotype A is the 
most potent neurotoxin of all and has the longest duration of action 
in a biological system. The main site of action of the toxin serotypes 
in vivo are peripheral cholinergic nerve endings, including the 
neuromuscular junction and both sympathetic and parasympathetic 
nerve terminals. Despite the potency of the protein, it can be used 
safely and effectively to manage a number of clinical conditions. 
Botulinum toxin type A (BoNT/A) was first licensed in 1992 as Botox 
Cosmetic® (Allergan, Inc., Irvine, CA., USA) for use in the reduction 
of glabellar lines. Carruthers & Carruthers [3] described the effect of 
BoNT/A (called onabotulinum toxin by Allergan) upon rhytids. The 
biological activity of BoNT/A is measured by the Speywood units 
which are determined by the median LD50 dose given as an intra-
peritoneal injection to Swiss-Webster mice.
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Botulinum toxin can enter and act on virtually any cell by 
a variety of mechanisms including false receptor implantation, 
liposome transport, and increasing membrane permeability [4]. The 
mechanism for activity of the toxin is mediated by dissociation of the 
150 kDa core protein of BoNT/A from its toxin-complex to enter 
the neuron by receptor mediated endocytosis [2, 5, 6]. Once inside 
the nerve, the disulphide bond is cleaved and the light and heavy 
chains of the toxic protein separate and disperse into the cytoplasm. 
The light chain has protease enzyme activity and, depending on the 
serotype, may act to cleave   any of its three substrate SNARE (Soluble 
N-ethyl-maleimide-sensitive-factor Attachment Receptor) proteins: 
synaptosomal associated protein 25 (SNAP-25), synaptobrevin and 
syntaxin. The binding of BoNT/A, for example with the light chain 
with SNAP-25 protein, prevents fusion of acetylcholine containing 
vesicles at the presynaptic membrane site. This results in the blockage 
of acetylcholine being released at the neuromuscular junction and 
loss of neurotransmitter prevents further signaling at this site and 
impairs normal functioning of the muscle.
Currently, BoNT/A is used therapeutically for the treatment of 
cervical dystonia, spasticity, blepharospasm, strabismus, hemifacial 
spasm, relief of musculoskeletal and neuropathic pain, mesenteric 
hypertrophy, hyperhidrosis and in facial aesthetics [7-9].
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Although the action of BoNT/A at the neuromuscular junction 
has been described, the additional actions upon other cholinergic 
nerve endings including noci-receptors has not been fully elicited 
[10]. BoNT/A also has an effect upon modulators of pain including 
substance P, glutamate and calcitonin gene-related peptide but the full 
mechanism is poorly understood [11]. The high toxicity of BoNT/A 
limits in vivo human studies due to practical and ethical issues. 
Calcein release assay is a sensitive method that avoids 
culture methodologies and is widely used to compliment the 
minimum inhibitory (MIC) and/or minimum lethal (MLC) 
concentrations experimentation [12]. The advantage of using this 
method is that the experiment can be repeated for the individual 
phospholipid components of the test microorganisms. We selected 
the following organisms Escherichia coli, Enterococcus faecalis, 
Staphylococcus aureus, Staphylococcus epidermidis, and Candida 
albicans in which literature indicated the major lipid constituents 
for these microbes were dioleoylphosphatidylethanolamine 
(DOPE), dioleoylphosphatidylglycerol (DOPG), cardiolipin and 
lysylphosphatidylglycerol (LyslPG) [13]. These commercially 
synthesized lipids were also tested alongside of the freshly extracted 
lipids to evaluate antimicrobial activity of the selected test organisms.
The purpose of this study was to investigate whether BoNT/A 
with the excipients included in Azzalure® (Ipsen Biopharm Ltd, 
Wrexham, UK.), may/may not affect growth of common human body 
commensal microorganisms. It is also possible that the integrity of 
the Azzalure® packaging, itself is instrumental in maintaining sterility 
of the vial (due to toxicity of the product stored in it), and/or if it is the 
nature of the purified endotoxin that has antimicrobial activity. The 
rationale being that if the product becomes contaminated while in 
clinical use, the likely contaminants will come from the practitioners, 
their clothing or the immediate environment. 
Materials and Methods
Ethical approval in the form of a written letter, was obtained for 
this study from the Research Ethics Committee, before commencing 
laboratory investigations in which all experimental procedures met 
the ethical guidelines of our academic institute. 
Vial contents, storage, and integrity
Twelve previously reconstituted vials as per manufacturers 
protocol of BoNT/A, specifically Botox® (Allergan, USA) and 
Azzalure® (Ipsen Biopharm Ltd., Wrexham, UK) in which the product 
had been used up for their therapeutic application were collected 
from the north of England and South Wales, UK. These vials were 
destined for disposal but, in view of planning ahead for this study, 
the empty vials were collected from various locations of UK, in a cool 
box and thereafter kept in a locked refrigerator for a period ranging 
from 24h to 12 months by the lead author (MT). At the start of the 
laboratory investigation, all the tubes appeared moist with traces of 
the reconstituted product left inside the vials. All vials were rinsed 
with 400µl sterile saline under class II safety cabinet conditions and 
100µl aliquots were inoculated separately onto plates of nutrient agar, 
yeast extract agar, Sabouraud agar, and tryptone soya agar plates. 
Nutrient agar plates were incubated for 48 h at 37°C, and malt extract 
agar plates were incubated at 30°C and  Sabouraud agar plates and 
tryptone soya agar were incubated for 5 days at 22°C.
Culture maintenance and dilution profiles/regimes
Pure cultures of common human body  flora  such as E. coli NCTC 
10418, E. faecalis NCIMB 775, S. aureus NCIMB 6571, S. epidermidis 
NCIMB 8558, and C. albicans NCYC 147, were cultured aerobically in 
the laboratory on nutrient agar plates and incubated for 48h at 37°C, 
and malt extract agar pl ates for yeast were incubated at 30°C for 5 days 
and  Sabouraud agar plates and tryptone soya agar were incubated at 
22°C  for 5 days. These commensals are implicated as contaminants 
where there are poor cross infection control measures. The cultures 
were originally purchased from the National Collection of Type 
Cultures (NCTC) operated by Public Health England, National 
Collection of Yeast Cultures (NCYC), and National Collection of 
Industrial, Food and Marine Bacteria (NCIMB) and maintained in a 
teaching microbiology laboratory at our academic institute.
E. coli, E. faecalis, S. aureus, S. epidermidis, were maintained on 
nutrient agar  (Oxoid Ltd, Basingstoke, UK) plates and C. albicans 
was maintained on malt extract agar (Lab M Ltd, Bury, UK) as 
described above.
Liquid cultures bacteria and yeast: E. coli, E. faecalis, S. aureus, 
and S.epidermidis were inoculated into freshly prepared, sterile 
nutrient broth (Oxoid) as per manufacturer’s instructions. All bacterial 
liquid cultures were incubated overnight  at 37°C in a Gallenkamp 
orbital shaker incubator set at 180 rpm (Gemini BV, Apeldoorn, The 
Netherlands). A discrete  colony of C. albicans was inoculated into 10 
ml of sterile malt yeast glucose peptone (MYGP) broth (malt extract 
1.5g, yeast extract 1.5g, glucose 5g, peptone 2.5g/500ml distilled 
water). The liquid culture was incubated overnight  at 30°C in the 
Gallenkamp orbital shaker incubator set at 180rpm as before.
Dilution profiles/regimes: All cultures were pelleted and washed 
three times in ¼ strength sterile Ringer’s  solution tablets purchased 
from Lab M Ltd (Bury, UK) with re-suspension of cells in between 
each centrifugation step, using a Sigma 3-16PK bench top centrifuge 
(Sigma-Aldrich, Dorset, UK) at 8,200 rpm for 10 min at 4°C. The 
resultant cell pellet was re-suspended in Ringer’s solution prepared 
using tablets as described before (Lab M Ltd., UK) and held on ice for 
testing the antimicrobial activity of Azzalure ® (BoNT/A trade name, 
Ipsen Biopharm Ltd, Wrexham, UK) and for extracting lipids (see 
section on total lipid bacterial extract below). 
In order to obtain an initially acceptable countable number of 
colonies, the suspensions were serially diluted down to 1x10-12 in 
sterile saline (0.9% sodium chloride solution) and drops of a fixed 
volume (25 and 50µl) E. coli, E. faecalis, S. aureus, S. epidermidis, and 
C. albicans, diluted cell suspension were pipetted onto the surface (in 
triplicate), of freshly poured, dried and pre-labeled agar plates for the 
cultivation of the test microorganisms for colony count of ~30-300. 
Drops of the yeast were incubated at 30°C for 24h and bacteria at 37°C 
for 24h. Following incubation the plates were checked for discrete 
colonies using a colony counter  (Stuart Scientific, Fisher Scientific 
UK Ltd, Loughborough, UK). The plates were photographed with a 
Canon 450D digital SLR camera  (Jessops, Leeds, UK), fitted with a 
standard 18-55mm lens. Colony forming units per milliliter (cfu/mL) 
were calculated according to the appropriate dilution factor using 
Image J software to count colonies/drop for each bacteria/yeast. 
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Assessment of Azzalure®antimicrobial activity using culturable 
methods: Following determination of the range of dilution in which 
discrete colonies could be estimated for subsequent experiments, 
bacteria and yeast were diluted with 0.9% sterile saline as for the 
dilution profiles. The Azzalure® (Ipsen Biopharm Ltd, Wrexham, UK) 
was reconstituted, according to the manufacturer’s instructions just 
before use, with 0.9% sterile saline to give a final concentration of 2 
Speywood  units/millilitre (2U/mL) of Azzalure® per 25µl of saline. 
For discrete colonies for each organism in the range of 30-300 
colonies/drop predetermined dilution for E. faecalis was 1x10-9, and 
for E. coli, S. epidermidis, S aureus, it was 1x10-10 and C. albicans 
was 1x10-4. A fixed volume of the cell suspension (25µl) and an 
equal volume (25µl) of 2U/mL Azzalure® (= 50µl final drop volume) 
in triplicate was applied onto their respective solid agar medium. 
Control plates consisted of a fixed volume (25µl) of the same diluted 
cell suspension to which 25µl sterile saline was added and placed as a 
drop (50µl) in triplicate, onto fresh media plates as for the Azzalure® 
test plates. Further controls were performed by spreading 100µl of 
the mixture prepared by adding 50µl of the reconstituted 2U/mL 
Azzalure® and 50µl sterile saline. The plates were exposed to the air in 
the microbiology laboratory for up to 4h. The plates were incubated 
at 30°C and at 37°C for 24h. 
All experiments were performed in triplicate and on three 
different occasions. Nutrient agar plates were incubated at 37°C for 
24h and the yeast extract plates were incubated at 30°C for 24h as 
before. Following incubation the plates were checked for differences 
in the number of colonies using a colony counter and photographed. 
Calcein release cell-free assay
A previously reported lipid extraction method [14,15] was used 
to extract total lipids from all test microorganisms (E. coli, E. faecalis, 
S. aureus, S. epidermidis and C. albicans). Essentially, a small volume 
(1 ml) of each of the cell suspensions in Ringer’s solution, (see section 
on dilution profiles/regimes above) was transferred into sterile 1.5 
mL Eppendorf® micro centrifuge tubes  and centrifuged for 10 min 
in the Sigma 1-14, microcentrifuge   (Sigma-Aldrich Ltd, Dorset, 
UK) at 14,000 rpm to form a bacterial cell pellet. Each cell pellet was 
re-suspended and mixed thoroughly by vortex mixing in 0.4 ml of 
Ringer’s solution to which was added, 1.5 ml of a 1:2 (v/v) chloroform 
- methanol mixture. 0.5 ml of Milli-Q-water (specific ≈ 18.2 MΩ cm) 
was then added to the tubes and mixed again by vortexing for 5 min 
before separating two phases of the solvents by centrifugation  using 
a Sigma 1-14 centrifuge (Sigma-Aldrich, Dorset, UK)  at 2850rpm, for 
5 min and 4°C. The top aqueous phase was removed and subsequently 
discarded and the lower organic layer was dried under N2 gas to ensure 
that all the solvent had evaporated prior to its use with creating a lipid 
film.
The lipid films prepared above were suspended in 70 mM calcein. 
The suspension was thoroughly mixed by vortexing for 5 min prior 
to sonication for 30 mins. The calcein loaded liposomes were purified 
from free calcein and the vesicles that failed to entrap calcein by using 
a Sephadex G75 gel filtration column (Sigma-Aldrich, Dorset, UK). 
Prior to separation, the gel filtration column was equilibrated for 13h 
in a buffer containing 20mM HEPES, 150 mM NaCl and 1.0 mM 
EDTA  (pH 7.4) . Following specimen loading, the column was eluted 
with 5 mM HEPES at pH 7.5.
Calcein release assay was performed at 20°C in the dark, by 
adding 2ml of buffer containing 20 mM HEPES, 150 mM NaCl and 
1.0 mM EDTA (pH 7.4)  with 20μl of calcein containing liposomes 
and a 20μl aliquot of Azzalure® at the fixed concentration used for 
facial aesthetics (2U/mL of Azzalure®). To measure total calcein 
release, 20µl of Triton X100 was used to dissolve the liposomes. The 
fluorescence intensities of released calcein was measured using a FP-
6500 spectrofluorometer (JASCO, Tokyo, Japan), with an excitation 
wavelength of 490nm and an emission wavelength of 520nm. The 
percentage of dye leakage was then calculated. The percentage lysis 
was calculated using the following equation where A = absorbance.
[ ]
[ ]
AzzalureA  –  [A ]Percentage lysis  100




The whole experiment was then repeated for the individual 
phospholipid components of the test microorganisms by preparing 
91.0 μm unilamellar liposomes. In order to investigate the main 
individual phospholipids of bacterial membranes DOPE, DOPG, 
cardiolipin and LyslPG were purchased from Avanti Polar Lipids 
and were used without further purification. Phospholipids (7.5 mg) 
were dissolved in chloroform, evaporated under a stream of nitrogen, 
placed under vacuum for overnight and then rehydrated using 70mM 
calcein. These calcein containing liposomes were purified using gel 
filtration chromatography as for extracted lipids for functional testing 
by Azzalure®. 
Statistical Analysis
The data from each species of bacteria and yeast tested for growth 
following contact with BoNT/A (Azzalure®) did not conform to 
normality and hence, the non-parametric Kruskal-Wallis test was 
performed and statistical analysis based on the null hypothesis that 
there was no difference between the mean calcein release across the 
different model membranes tested was undertaken using an ANOVA 
test (Minitab 16 statistical analysis software, Minitab Inc., State 
College, PA, USA). 
Figure 1: Each organism tested following immediate contact with the product 
compared with the saline control. There was no statistical difference in any of 
the microorganism tested C. albicans p = < 0.05.
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Results
Vial contents, storage, and integrity
Following exposure of the reconstituted Azzalure® coated plates to 
the air (for 4h), all plates remained free of any air borne contaminants 
when checked by incubation of the plates at 30°C and at 37°C for up 
to 3 days. 
One white/cream coloured  colony, was observed on the nutrient 
agar from vial 10. The bacterial colony from vial 10 resembled the 
colonies growing on nutrient agar plates with known cultures of 
S,aureus. Its molecular identity was not examined. No growth was 
observed from any of the other vials (numbers 1-9 and 11-12).
The effect of BoNT/A on the growth of bacteria and yeast 
There was no statistical difference in any of the microorganism 
tested by immediate contact with the product p ≤ 0.05 compared to 
those that contacted saline in controls (Figure 1 ). The colony counts 
varied between the three different sets of experiments as indicated by 
large error bars.
The lytic ability of azzalure® calcein release assay
An antimicrobial compound can kill bacteria through many 
different mechanisms. The calcein release assay is an accepted 
methodology and in this study we used it to further determine to 
what extent Azzalure® may cause membrane disruption. The use of 
large unilamellar bacterial lipid extract liposomes loaded with calcein 
enables the membrane disruption to be assessed. In general, the 
probe is used to assess the increase in fluorescence when the calcein 
(florophore) is released due to membrane leakage.
Figure 2 shows low levels of calcein leakage in the presence of 
Azzalure®.  These data correlate with the MIC data, suggesting that 
Azzalure® and/or its additives have low levels of antimicrobial activity. 
Whilst these differences in calcein release after 2h for bacterial lipid 
extract remain statistically significant (p = 0.011) the levels of release 
remained low for each organism. However, after 15h there was a 
significant difference in calcein leakage for Azzalure® in the presence 
of liposomes prepared from the lipid extract [F = 51.420; p = 0.0001]. 
For liposomes formed from E. coli lipid  membrane extract, Azzalure® 
caused greater levels of leakage (34%) and was statistically significant 
compared to E. faecalis, S. aureus, and C. albicans (p ≤ 0.05). However, 
there was no significant difference in calcein leakage for liposomes 
formed from E. coli and S. epidermidis lipid extract (p = 0.29).
The bacterial lipid membrane composition varies from bacterium 
to bacterium. PG is known as a major component in Gram-
positive bacteria whereas PE is identified as the major membrane 
component in Gram-negative bacteria [12]. Hence, the main lipid 
components of the organisms employed were investigated within 
these systems. Figure 3 shows that Azzalure® has a preference for 
anionic lipid LyslpePG, cardiolipin and DOPG. Of these, PG is the 
main phospholipid component of all the test microorganisms. There 
was a significant difference in the mean calcein release after 15h 
incubation in all of the model commercial lipid vesicles [F = 71.482; 
p = 0.0001] as shown in Figure 3. However, further statistical analysis 
demonstrated that there was no difference in the percentage of calcein 
released in the presence of Azzalure® following 15h incubation in all 
of the freshly extracted bacterial lipids and of the model commercial 
lipid liposomes. However in the extracted yeast lipid, there was a 
significant difference in lysis (p ≤ 0.05).
Discussion
As C. botulinum toxin type A or BoNT/A is used in facial 
aesthetics, in which the manufacturer’s very stringent and strict 
guidelines for product use must be followed, it was postulated that 
the manufacturer’s guidelines may be seeking to reduce the risk 
of contamination and/or loss in the efficacy of the re-constituted 
therapeutic product if used outside the recommended window of use 
of 4h. Since, literature supports the efficacy of BoNT/A protein to 
remain intact after reconstitution and storage up to one month and 
longer at 4°C and up to six months at -20°C [8,14,15] this investigation 
determined whether multi-use vials are susceptible to becoming 
contaminated during longer storage and/or following deliberate 
contamination of Azzalure® (Ipsen, UK), with known commensal 
human body flora. In addition, excipients are included in Azzalure® 
(Ipsen, UK), and their role as additional additives to the therapeutic 
product is unclear to the end user. This investigation employed, the 
cost effective, droplet method of Miles and Misra [16] designed to 
provide a rapid, reproducible method of counting microorganisms 
Figure 2: Percentage calcein leakage of botox for E. coli (grey crosses), E. 
faecalis (light grey crosses), S. aureus (solid grey circles), S. epidermidis 
(black crosses) and C. albicans (grey circles) lipid extract vesicles. The 
values shown in the figure are the average and standard deviations of four 
experiments.
Figure 3: Percentage calcein leakage of botox for LysylPG (black crosses), 
Cardiolipin (grey crosses), DOPE (grey circles) and DOPG (black circles) 
vesicles. The values shown in the figure are the average and standard 
deviations of four experiments.
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challenged with Azzalure® (Ipsen, UK). The procedure was performed 
under controlled laboratory conditions, to compare levels of microbial 
viability with appropriate controls.
 Next we verified our results by washing out of reconstituted 
therapeutic product Botox® and Azzalure® from vials after the product 
had long been used up for periods of a few hours to 12 months. 
Overall, our results are in agreement with the findings of the previous 
two investigations in that 11 out of 12 vials maintained sterility 
[17,18] and that cross contamination is possible. The reasoning for 
the one vial (vial number 10) which demonstrated growth of white/
cream coloured single bacterial colony was likely the result of a 
splash/cross contamination during pipetting of S. aureus. However 
as no attempt was made to find the exact molecular identity of the 
bacterium, the contaminating organism and contamination of the 
vial remains unresolved. 
Literature suggests that BoNT/A can adversely affect virtually 
any cell-type [4] and the saline (other than bacteriostatic saline) used 
for reconstituting the product may add to the stress of fewer bacteria 
and yeast cells if they were to contaminate the vials during handling. 
Additional “additives” that have the ability to reduce vial wetting [19] 
and the prevention of resistance to liquid ingress, can occur [20], 
and these help to create an environment within the vial which may 
limit the survival of contaminating microorgamisms. How long this 
environment could resist contamination is unknown but the results of 
this study suggest that after 12 months of appropriate storage, except 
for the one vial in which bacterial growth was recorded, no significant 
contamination had occurred in the remaining used vials. This leads to 
the conclusion that majority of the vials tested here remained sterile. 
This is likely to be due to the integrity of the Azzalure® packaging, 
itself rather than the purified endotoxin that demonstrated little 
antimicrobial activity.
Next we challenged Azzalure® (Ipsen, UK) with selected 
laboratory strains of test microorganisms to investigate any effect 
on their growth and viability. The selected test organisms included 
common commensals of the human body which have been implicated 
as contaminants where poor infection control has been observed. The 
effect of Azzalure® (Ipsen, UK) at the therapeutic dose, recommended 
for non-surgical facial aesthetics, and as measured by Speywood 
units/millilitre (U/mL) was tested on the selected organisms and 
was compared to controls without the product but under the same 
experimental conditions. 
The experimental procedure used to evaluate the antimicrobial 
activity of Azzalure® (Ipsen, UK) demonstrated that statistically, 
there was no significant difference between the cfu/drop between the 
control and test samples for all five microorganisms. 
In order to investigate the lytic ability of BoNT/A, a calcein 
release assay was undertaken using bacterial lipid extract and 
commercial lipids such as, DOPE, DOPG, cardiolipin and LyslPG 
[13]. The phospholipid composition of a cell membrane is essential 
in the selectivity of an antimicrobial compound [12]. The variation 
in the lipid composition and compound interaction is also dependent 
on phospholipid packing characteristics and stability [12]. The 
calcein release assay showed that BoNTA had a preference for 
anionic phospholipid headgroups PG, which is the main component 
of S. aureus, S.epidermidis and E. faecalis membranes. In a membrane 
with reduced negative charge the Azzalure®–NH2 may be attracted to 
the positive charges of the phospholipids in a bacterial membrane. 
In contrast, in the presence of phosphatidylethanolamine (PE), a 
reduced level of calcein lysis was observed indicating that since the 
lipid composition of E. coli membranes includes 91% PE, 3% PG, 
and 6% CL [13], this high level of PE content offers a protection 
against leakage. It is possible that the local interaction of the BoNT/A 
to the membrane requires binding of the BoNT/A to the target cell 
membrane. Furthermore, this initial interaction appears important for 
its binding to the neurotransmitter vesicles [4]. One of the excipients 
added to Azzalure® is albumin and is believed to encourage microbial 
growth. This inference is made from the reported observations that 
an infectious episode in the human host for example, decreases the 
normally high concentration of albumin during acute-phase [21]. A 
possible reason for this down regulation is for the innate immune 
responses to act to inhibit growth of bacteria invading the host.
In conclusion, except for the one out of 12 vials tested, majority 
of the vials remained sterile. The vial and stopper seem to be effective 
against microbial contamination even when the contents were 
accessed multiple times in our hands. It is therefore the integrity of 
the packaging of the multi-use vial over the antimicrobial activity of 
the product that protects the vial from being easily infected. This leads 
to the conclusion that BoNT/A is safe and effective if manufacturer’s 
instructions are followed.
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